![PDF) LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the "LOWERING-IT" Trial PDF) LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the "LOWERING-IT" Trial](https://www.researchgate.net/profile/Ferdinando-Carlo-Sasso/publication/45090126/figure/fig1/AS:667199467446274@1536084157191/figure-fig1_Q320.jpg)
PDF) LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the "LOWERING-IT" Trial
![2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation](https://www.ahajournals.org/cms/asset/371edd3f-74d6-495a-86b7-1a6881373c0d/cir.0000000000000923.tab04.gif)
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
![Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario | SpringerLink Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12055-019-00789-z/MediaObjects/12055_2019_789_Fig3_HTML.png)
Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario | SpringerLink
![Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis - ScienceDirect Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022522319305069-gr6.jpg)
Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis - ScienceDirect
CorConsult Rx - #Repost from @ambcarerx ・・・ Warfarin review! INR goals for most warfarin indications are 2-3, except unless patient has a mechanical mitral valve replacement, in which the INR goal would
![Chris McAloon on Twitter: "ESC 2012 Guidelines on Target INR for Mechanical Valves (note types of valve & risk factors) #CardioEd #EEGC https://t.co/wpbVk30frW https://t.co/NqUjRIqdVu" / Twitter Chris McAloon on Twitter: "ESC 2012 Guidelines on Target INR for Mechanical Valves (note types of valve & risk factors) #CardioEd #EEGC https://t.co/wpbVk30frW https://t.co/NqUjRIqdVu" / Twitter](https://pbs.twimg.com/media/DA-poORU0AMUX-X.jpg)
Chris McAloon on Twitter: "ESC 2012 Guidelines on Target INR for Mechanical Valves (note types of valve & risk factors) #CardioEd #EEGC https://t.co/wpbVk30frW https://t.co/NqUjRIqdVu" / Twitter
![BOTH Aspirin and Warfarin are needed for anticoagulation following mechanical valve replacement... t… | Medical school stuff, Aortic valve replacement, Mitral valve BOTH Aspirin and Warfarin are needed for anticoagulation following mechanical valve replacement... t… | Medical school stuff, Aortic valve replacement, Mitral valve](https://i.pinimg.com/originals/1f/e9/49/1fe94982820af423556de25c8e3b346b.png)
BOTH Aspirin and Warfarin are needed for anticoagulation following mechanical valve replacement... t… | Medical school stuff, Aortic valve replacement, Mitral valve
![Alfonso Valle on Twitter: "💡Bioprosthetic SAVR or mitral valve replacement➡️Anticoagulation with VKA to an INR of 2.5 is reasonable for 3-6 months postoperatively (Class 2b) 💡On-X AVR ➡️ INR of 1.5-2.0, starting Alfonso Valle on Twitter: "💡Bioprosthetic SAVR or mitral valve replacement➡️Anticoagulation with VKA to an INR of 2.5 is reasonable for 3-6 months postoperatively (Class 2b) 💡On-X AVR ➡️ INR of 1.5-2.0, starting](https://pbs.twimg.com/media/Epf_4bMXYAApE0c.jpg)
Alfonso Valle on Twitter: "💡Bioprosthetic SAVR or mitral valve replacement➡️Anticoagulation with VKA to an INR of 2.5 is reasonable for 3-6 months postoperatively (Class 2b) 💡On-X AVR ➡️ INR of 1.5-2.0, starting
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of
![Comparison of warfarin dosage needed to achieve target INR before and after cardiac surgery - The British Journal of Cardiology Comparison of warfarin dosage needed to achieve target INR before and after cardiac surgery - The British Journal of Cardiology](https://bjcardio.co.uk/wp-content/uploads/2016/01/table-14.png)
Comparison of warfarin dosage needed to achieve target INR before and after cardiac surgery - The British Journal of Cardiology
![U.S. FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients | Business Wire U.S. FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients | Business Wire](https://mms.businesswire.com/media/20150402005154/en/460461/5/On-x_heart_valve_Infographic_highres.jpg)
U.S. FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients | Business Wire
![Heart valve disease module 7: anti-thrombotic therapy for valvular heart disease - The British Journal of Cardiology Heart valve disease module 7: anti-thrombotic therapy for valvular heart disease - The British Journal of Cardiology](https://bjcardio.co.uk/wp-content/uploads/2015/12/Screen-shot-2015-12-15-at-15.35.11.png)